Zydus Lifesciences subsidiary launches Trokendi XR generic in US

Zydus Lifesciences (previously Cadila Healthcare) said that its subsidiary Zydus Pharmaceuticals (USA) Inc. has launched Topiramate Extended-Release Capsules in the US.

The launch follows the final approval received by Zydus Pharmaceuticals (USA) from the US Food and Drug Administration (FDA) for marketing Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg.

The approved product is the generic of Trokendi XR (topiramate), a carbonic anhydrase inhibitor indicated for the treatment of epilepsy and the prevention of migraines.

Zydus Lifesciences subsidiary launches Trokendi XR generic in US. Photo courtesy of Zydus Cadila.

According to IQVIA data, the annual sales of Topiramate Extended-Release capsule in the US was $488 million.